EUVIMEDEUVIMED entdecken
Open Access

The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity

Daniel J Betensky, Karen C Smith iD, Jeffrey N Katz iD, Catherine Yang, David J Hunter iD, Jamie E Collins iD, Candace H Feldman iD, Stephen P Messier, Jason S Kim iD, Faith Selzer, A David Paltiel iD, Elena Losina iD

Annals of Internal Medicine · 2025-11 · 178 (11) · 1549-1560

DOI: 10.7326/annals-24-03609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Internal Medicine, 2025-11. Verfasst von Daniel J Betensky und 11 weiteren Autor:innen. Beteiligte Einrichtung: Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Center and Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Depar…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Osteoarthritis, Knee, Obesity, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP1RAs) lead to substantial weight loss and pain reduction in persons with knee osteoarthritis and obesity. OBJECTIVE: To evaluate the cost-effectiveness of 2 GLP1RAs, semaglutide and tirzepatide, for patients with osteoarthritis and obesity. DESIGN: Osteoarthritis Policy Model, a validated microsimulation model of knee osteoarthritis, to estimate lifetime benefits and costs of weight loss strategies. DATA SOURCES: Published data to derive treatment-related weight loss, pain reduction, and costs of GLP1RAs from the U.S. Office of Health Policy. TARGET POPULATION: Persons with knee osteoarthritis and obesity in the United States. The base-case cohort had a Western Ontario and McMaster Universities Osteoarthritis Index pain score of 71 (0 to 100, 100 worst) and a mean body mass index (BMI) of 40 kg/m2. TIME HORIZON: Lifetime. PERSPECTIVE: Health care, societal. INTERVENTION: Semaglutide, tirzepatide, laparoscopic sleeve gastrectomy (LSG), Roux-en-Y gastric bypass (RYGB), and diet and exercise. OUTCOME MEASURES: Quality-adjusted life-years (QALYs), cost, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: Tirzepatide provided greater health benefits at lower costs than semaglutide and yielded a $57 400 per QALY ICER versus diet and exercise. For those eligible, RYGB provided greater health benefits at lower costs than the 2 GLP1RAs and had a $30 700 per QALY ICER versus LSG. RESULTS OF SENSITIVITY ANALYSIS: Tirzepatide's ICER was most sensitive to changes in medication costs, treatment efficacy, and cohort baseline BMI. Tirzepatide had a 64% and semaglutide had a 34% probability of being cost-effective at a $100 000 per QALY threshold. LIMITATION: Data from multiple sources. CONCLUSION: Both tirzepatide and semaglutide would be widely considered cost-effective when compared directly with usual care. Tirzepatide would offer the most favorable return on investment to decision makers whose cost-effectiveness thresholds exceed $57 400 per QALY. PRIMARY FUNDING SOURCE: The Arthritis Foundation and National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesOsteoarthritis, KneeObesityGlucagon-Like Peptide-1 Receptor AgonistsHumansCost-Benefit AnalysisQuality-Adjusted Life YearsTirzepatideWeight LossMiddle AgedFemaleMaleGlucagon-Like Peptide 1Semaglutide

Substanzen

Glucagon-Like PeptidesTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Center and Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, Ma…
  • Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Center and Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Department of Orthopaedic Surgery, Brigham and Women's Hospital; and Harvar…
  • Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Center and Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Department of Orthopaedic Surgery, Brigham and Women's Hospital; Harvard Me…
  • Rheumatology Department, Royal North Shore Hospital and Sydney Musculoskeletal Health, Kolling Institute, University of Sydney, Sydney, Australia (D.J.H.).
  • Harvard Medical School and Section of Clinical Sciences, Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, Massachusetts (C.H.F.).
  • J.B. Snow Biomechanics Laboratory, Department of Health and Exercise Science, Wake Forest University, Winston-Salem, North Carolina (S.P.M.).

ORCID-Profile: Karen C Smith, Jeffrey N Katz, David J Hunter, Jamie E Collins, Candace H Feldman, Jason S Kim, A David Paltiel, Elena Losina

Förderung

  • NIAMS NIH HHS

Zitieren

APA

Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J. S., Selzer, F., Paltiel, A. D., & Losina, E. (2025). The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity. Annals of Internal Medicine, 178(11), 1549-1560. https://doi.org/10.7326/annals-24-03609

Vancouver

Betensky DJ, Smith KC, Katz JN, Yang C, Hunter DJ, Collins JE, et al. The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity. Annals of Internal Medicine. 2025;178(11):1549-1560. doi:10.7326/annals-24-03609

BibTeX
@article{Betensky2025,
  author = {Betensky, Daniel J and Smith, Karen C and Katz, Jeffrey N and Yang, Catherine and Hunter, David J and Collins, Jamie E and Feldman, Candace H and Messier, Stephen P and Kim, Jason S and Selzer, Faith and Paltiel, A David and Losina, Elena},
  title = {The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity},
  journal = {Annals of Internal Medicine},
  year = {2025},
  volume = {178},
  number = {11},
  pages = {1549--1560},
  doi = {10.7326/annals-24-03609}
}
Kostenlos starten →